caa a22 4500 475819187 CHVBK 20180406123817.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1007/s002280000222 doi (NATIONALLICENCE)springer-10.1007/s002280000222 CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients [Elektronische Daten] [M.G. Scordo, E. Spina, P. Romeo, M.-L. Dahl, L. Bertilsson, I. Johansson, F. Sjöqvist] Abstract. : Objective: In order to evaluate whether poor metabolizers (PM) of debrisoquine are overrepresented among patients with acute dystonic reactions and chronic movement disorders associated with the administration of antipsychotic drugs, the CYP2D6 genotype was determined in schizophrenic patients. Methods: Allele status for CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*6 as well as gene duplication was determined by allele-specific PCR, long-PCR and restriction fragment length polymorphism analysis (RFLP) in 119 schizophrenic patients (99 males and 20 females). All subjects were treated with antipsychotics metabolized, at least partially, by this isozyme. Sixty-three of the patients (52.9%) had a history of extrapyramidal side effects (EPS), while 56 (47.1%) had not experienced such problems (controls). Results: Sixty-five patients (54.6%) were homozygous for a functional CYP2D6*1 allele, 44 (37.0%) were heterozygous for detrimental alleles, and 4 (3.4%), who carried two detrimental alleles, were classified as PM. In six patients (5.0%) duplication of a functional CYP2D6 gene was found, and they were consequently classified as ultrarapid metabolizers (UM). Homo- and heterozygous extensive metabolizers (EM) as well as UM were equally distributed between patients with and without EPS, whereas all the PM had a history of EPS. No significant differences in allele frequencies between the two groups were found. Conclusion: Although the results cannot be considered conclusive due to the small number of PM patients in our study, the PM genotype may be a predisposing factor for antipsychotic-induced EPS. Knowledge of the CYP2D6 genotype, before starting antipsychotic therapy, might be useful in identifying subjects at risk of developing EPS. Springer-Verlag, 2000 CYP2D6 Genotype Antipsychotic drugs Extrapyramidal side effects nationallicence Scordo M.G. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut Spina E. Institute of Pharmacology, University of Messina, Torre Biologica, Policlinico Universitario, Via Consolare Valeria, Gazzi, 98125 Messina, Italy aut Romeo P. Institute of Psychiatry, University of Messina, Messina, Italy aut Dahl M.-L Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut Bertilsson L. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut Johansson I. Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, Stockholm, Sweden aut Sjöqvist F. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut European Journal of Clinical Pharmacology Springer-Verlag 56/9-10(2000-12-01), 679-683 0031-6970 56:9-10<679 2000 56 228 https://doi.org/10.1007/s002280000222 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000222 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Scordo M.G. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut NATIONALLICENCE 700 1- Spina E. Institute of Pharmacology, University of Messina, Torre Biologica, Policlinico Universitario, Via Consolare Valeria, Gazzi, 98125 Messina, Italy aut NATIONALLICENCE 700 1- Romeo P. Institute of Psychiatry, University of Messina, Messina, Italy aut NATIONALLICENCE 700 1- Dahl M.-L Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut NATIONALLICENCE 700 1- Bertilsson L. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut NATIONALLICENCE 700 1- Johansson I. Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 700 1- Sjöqvist F. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 56/9-10(2000-12-01), 679-683 0031-6970 56:9-10<679 2000 56 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer